CN1072949C - Medicine for treating anorexia - Google Patents
Medicine for treating anorexia Download PDFInfo
- Publication number
- CN1072949C CN1072949C CN98113029A CN98113029A CN1072949C CN 1072949 C CN1072949 C CN 1072949C CN 98113029 A CN98113029 A CN 98113029A CN 98113029 A CN98113029 A CN 98113029A CN 1072949 C CN1072949 C CN 1072949C
- Authority
- CN
- China
- Prior art keywords
- present
- medicine
- portions
- group
- examples
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to a Chinese patent medicine for curing anorexia. Traditional Chinese medicines, such as musk, melanterite, jujube flesh, hawthorn, yam and areca seed, are used as raw materials to prepare powder or capsules or tablets by the conventional formulation method. Experiments in pharmacodynamics prove that the present invention obviously adjusts gastrointestinal motility and is favorable for improving a plurality of symptoms caused by spleen vacuity. Through 124 cases of primary clinical observation experiments, the result indicates that the present invention has the advantages of no toxic or side effect, conspicuous therapeutic effect, etc. The total effective rate is 92.30%, and the Chinese patent medicine for curing anorexia can be widely used in clinical practice by further and clinically enlarging experiments.
Description
The invention belongs to the medicinal preparation technical field of the product that contains raw material or fuzzy structure, being specifically related to a kind of is the Chinese patent medicine of the treatment apositia made of raw material with botanical herbs with the mammal.
Apositia is a kind of disease of patient's appetite minimizing in a long time or disappearance, and wherein child's sickness rate is higher.The medicine that is used for the treatment of apositia clinically is a lot, and Western medicine has polyzyme tablets, behind patient's clothes, increases the digestive enzyme in the intestines and stomach, facilitating digestion, no therapeutic efficiency.The Chinese patent medicine of treatment apositia has lenitive pill, spleen-strengthening bolus, and lenitive pill is mainly used in food stagnation, the treatment apositia, specific aim is strong, it is slow to take effect, the course of treatment is long, curative effect is not remarkable, spleen-strengthening bolus is used for insufficiency of the spleen dysfunction of the spleen in transportation and transformation, is used for deficient syndrome clinically, and is not remarkable to the apositia curative effect.
The objective of the invention is to have no side effect for apositia provides a kind of, the significant Chinese patent medicine of therapeutic effect.
For achieving the above object, it is the Chinese patent medicine of making than (consumption is a weight portion) with following set of dispense for the solution that the present invention adopts:
20～40 parts in 8～20 portions of Fructus Jujubaes of 0.2～0.6 part of Melanteritum of Moschus
8～18 parts of 26～34 portions of Semen Arecaes of 20～40 portions of Rhizoma Dioscoreaes of Fructus Crataegi
The proportion optimization weight ratio scope of preparation medicine of the present invention is:
25～35 parts in 10～15 portions of Fructus Jujubaes of 0.3～0.5 part of Melanteritum of Moschus
10～18 parts of 26～32 portions of Semen Arecaes of 25～35 portions of Rhizoma Dioscoreaes of Fructus Crataegi
The optimum weight proportioning of preparation medicine of the present invention is:
32 parts in 12 portions of Fructus Jujubaes of 0.4 part of Melanteritum of Moschus
14 parts of 28 portions of Semen Arecaes of 30 portions of Rhizoma Dioscoreaes of Fructus Crataegi
The medicament that above-mentioned each component is made according to a conventional method is said powder or capsule or a tablet on the galenic pharmacy, also can be made into oral liquid.
The preparation technology of powder of the present invention is as follows:
1. get raw material, choose decontamination and the part of going mouldy, its quality is checked that Melanteritum and Fructus Crataegi are concocted by Chinese Pharmacopoeia, weigh by proportioning by Chinese Pharmacopoeia.
2. get Melanteritum and be ground into 100 order fine powders.Get Fructus Crataegi, Semen Arecae, Rhizoma Dioscoreae and Fructus Jujubae mixed powder and be broken into 100 order fine powders,, make drug powder of the present invention with Melanteritum fine powder and the little mixing that grinds of Moschus.
3. by the quality standard check of drug powder of the present invention, every gram drug powder of the present invention contains crude drug 1g, in the plastic bag of behind ultraviolet disinfection, packing into, and every bag heavy 0.5g.
The preparation technology of medicine capsule of the present invention is as follows:
Promptly make medicine capsule of the present invention in prepared drug powder of the present invention incapsulated, every heavy 0.5g.Proportioning raw materials that capsule is used and preparation technology press capsule proportioning raw materials preparation technology's making routinely on the galenic pharmacy.
The preparation technology of medicinal tablet of the present invention is as follows:
Prepared drug powder of the present invention is granulated with 10% starch gelatin slurry, 10% starch gelatin slurry consumption is 4% of medicinal tablet of the present invention, cold drying, pulverized 100 mesh sieves, granulated cold drying with moistening 14 mesh sieves that pass through of 55% ethanol, again by 12 mesh sieve granulate, add the magnesium stearate lubricant, the consumption of magnesium is 0.23% of medicinal tablet of the present invention, tabletting.Every heavy 0.3g, every gram crude drug content 0.96g, after quality examination, ultraviolet disinfection, packing.
It can increase the emptying ability of mice stomach to medicine of the present invention through pharmacodynamics test proof, improves the intestinal activity, can resist simultaneously because of the weight loss due to insufficiency of the spleen, has improvement to be inclined to body temperature.Medicine of the present invention has more obviously adjusts gastrointestinal motility, helps improving insufficiency of the spleen some symptoms that occur.Medicine of the present invention is through the test of 124 routine Preliminary Clinical Observation, and the result shows that the present invention has advantage such as have no side effect, evident in efficacy, and total effective rate is 92.30%, further can promote the use of clinically after the expanding test clinically.
For showing the therapeutic effect of medicine of the present invention to apositia, application is gone into consignment test unit medicine of the present invention (test name is the appetizing spirit) has been carried out pharmacodynamics and Preliminary Clinical Observation test, and test situation is as follows:
One, pharmacodynamics test
Reagent and be subjected to the reagent thing: motilium is produced by Xian-Janssen Pharmaceutical Ltd., and spleen-strengthening bolus is produced by Lanzhou Fo Ci pharmaceutical factory, provided by the trustee for medicine of the present invention by the reagent thing.
1. medicine of the present invention is to the influence of mice gastric emptying
Test method: 90 of mices, body weight 20.11 ± 1.04g, the male and female dual-purpose, be divided into six groups at random, i.e. dosage group (0.75g/kg.po), medicine small dose group of the present invention (0.38g/kg.po) in tap water matched group (10ml/kg.po), moulding group (atropine 1mg/kg.H), positive drug motilium group (10mg/kg.po), the heavy dose of group of medicine of the present invention (1.5g/kg.po), the medicine of the present invention.Every day gastric infusion once, successive administration 7 days, fasting is 24 hours before the experiment, except that matched group, all the other respectively organize the equal subcutaneous injection atropine of mice 1mg/kg, irritate stomach after 20 minutes and give medicine of the present invention and 0.1% methyl orange (0.2ml/ only), mice takes off cervical vertebra execution after 20 minutes, cuts open the belly, clamp the cardia and the pyloric part of stomach with mosquito forceps, stomach is cut off along greater gastric curvature, with 10ml distilled water flushing gastric content, flushing liquor on centrifuge centrifugal 15 minutes with 3000rpm speed, get supernatant under the 420nm light wave, with 721 type spectrophotometer colorimetrics, calculate methyl orange at the gastric residual rate, organize a t test.
Result of the test: medicine 0.38g/kg dosage of the present invention obviously reduces the residual rate (p＜0.05) of methyl orange at gastric, shows that medicine of the present invention can strengthen the stomach motion of being slowed down by intestine evacuation velocity due to the atropine.Experimental group is compared with matched group, Δ Δ p＜0.01, and experimental group is compared with the moulding group, * p＜0.05, * * p＜0.01.
2. medicine of the present invention is to the influence of mouse small intestine motion
Test method: 90 of mices, body weight 20.36 ± 1.09g, male and female dual-purpose.Be divided into six groups at random, be dosage group (0.75g/kg), medicine small dose group of the present invention (0.38g/kg) in tap water matched group (10ml/kg), moulding group (atropine 1mg/kg.H), positive drug motilium group (10mg/kg), the heavy dose of group of medicine of the present invention (1.5g/kg), the medicine of the present invention, every day gastric infusion, continuous 7 days.Fasting is 24 hours before the experiment, except that control group mice, all the other respectively organize the equal subcutaneous injection atropine of mice 1mg/kg, irritate stomach after 20 minutes and give thing of the present invention and prepared Chinese ink (10ml/kg), after 20 minutes mice being taken off cervical vertebra puts to death, cut open the belly, take out from pylorus digestive tube, do not add traction and be tiled on the glass plate to the small intestinal total length, survey its total length and prepared Chinese ink forward position distance to pylorus, calculate the percentage ratio of itself and total length, promptly the intestinal propulsion percentage rate is organized a t check.
Result of the test: medicine 0.38g/kg dosage of the present invention can obviously strengthen the intestinal motility (p＜0.05) that slows down because of peristaltic velocity due to the atropine.Experimental group and matched group be Δ Δ p＜0.01 relatively, and experimental group and moulding group compare, * p＜0.0 5, * * p＜0.01.
3. medicine of the present invention causes the influence of Mice with Spleen model to eating and drinking without temperance
Test method: 90 of mices, body weight 27.42 ± 2.0, male and female dual-purpose.Be divided into six groups at random, be tap water matched group (10ml/kg), moulding group (refined lard 0.5ml/ only), positive drug control group (spleen-strengthening bolus 1.36g/kg), the heavy dose of group of medicine of the present invention (1.5g/kg), dosage group (0.75g/kg) in the medicine of the present invention, medicine small dose group of the present invention (0.38g/kg), outside the matched group feed every day material, the tap water matched group is irritated stomach to tap water every day, positive drug control group is irritated the stomach spleen-strengthening bolus every day, the moulding group is except that every day feed material, irritating stomach every day gives refined lard 0.5ml/ only, continuous 9 days, experimental group is irritated stomach to outside the medicine of the present invention every day, and all the other are all with the moulding group.Every day administration before measurement body weight and body temperature, every day, forage volume and the amount of drinking water of mice respectively organized in record, observes mice behavior and fur situation simultaneously.Each measured value is organized a t check.
Result of the test; Medicine 0.75g/kg of the present invention can improve because of the weight loss (p＜0.05) due to insufficiency of the spleen, and body temperature due to insufficiency of the spleen is descended the tendency of raising, and foodstuff and the amount of drinking water of mice do not had tangible influence.Moulding group mice generally is slow in action, and dry skin and hair is at random, and drug study group mice of the present invention all has improvement in various degree.Medicine of the present invention is to the influence of mice body weight, and experimental group and matched group compare, Δ Δ p＜0.01, and experimental group and moulding group compare, * p＜0.0 5, * * p＜0.01, medicine of the present invention is to the influence of mouse temperature, and experimental group and matched group compare, Δ＜0.5.
Results of pharmacodynamic test shows that medicine of the present invention can increase the emptying ability of mice stomach, improves the intestinal activity, can resist simultaneously because of the weight loss due to insufficiency of the spleen, has improvement to be inclined to body temperature.Therefore, medicine of the present invention has more obviously adjusts gastrointestinal motility, helps improving insufficiency of the spleen some symptoms that occur, and these results are used to regulate spleen and stomach function clinically to medicine of the present invention provides pharmacological basis.
Two, Preliminary Clinical Observation test
1. diagnostic criteria: by the 3rd volume of 26 pages of definite anorexia of Chinese traditional Chinese medical science industry standard " new Chinese medicine clinical research guideline " is diagnosis basis.
2. state of an illness calibration
The apositia state of an illness can be divided into slightly, moderate, severe three degree.Slightly: appetite more on ordinary days or child of the same age reduce 1/3, feed has is sick of sense, particular about food or monophagia; Moderate: appetite reduces 1/2, need force feed; Severe: appetite reduces more than 1/2, refusing to eat, and strong food is then felt sick.Hyperhidrosis can be divided into three grades in profuse sweating, middle antiperspirant, little antiperspirant, profuse sweating: panhidrosis; Middle antiperspirant: head hyperhidrosis, trunk hypohidrosis; Little antiperspirant: only head is perspired.
3. clinical data: be diagnosed as apositia patient 124 examples by the diagnosis standard, be divided into treatment group, contrast I group, contrast II group at random.52 examples are organized in treatment, male 30 examples, women 22 examples, and minimum 2 years old 2 months of age, maximum 16 years old, the course of disease is the shortest 2 months, the longest 10 years, average 2 years 10 months, 8 examples that anorexia is slight, moderate 35 examples, severe 9 examples, profuse sweating 10 examples, middle antiperspirant 21 examples, little antiperspirant 11 examples.Contrast I group 42 examples, male 24 examples, women 18 examples, minimum 2 years old 6 months of age, maximum 11 years old 9 months, the course of disease is the shortest 2 months, the longest 9 years, average 2 years 6 months, 6 examples that anorexia is slight, moderate 26 examples, severe 10 examples, profuse sweating 7 examples, middle antiperspirant 16 examples, little antiperspirant 10 examples.Contrast II group 30 examples, male 20 examples, women 10 examples, minimum 1 years old 11 months of age, maximum 11 years old, the course of disease is the shortest 1 year 5 months, the longest 8 years, average 2 years 7 months, 5 examples that anorexia is slight, moderate 17 examples, severe 8 examples, profuse sweating 8 examples, middle antiperspirant 15 examples, little antiperspirant 7 examples.Three groups of clinical datas are learned by statistics and are handled basic neat (p＞0.1) together.
4. trial drug
1. medicament capsule of the present invention, every heavy 0.5g, every gram crude drug content 1g; 2. controlled trial medicament capsule, the few Moschus of the component of its ratio of component medicine of the present invention, Fructus Crataegi, content is identical; 3. like the sugar slurry and be city's pin commodity.
5. Therapeutic Method: oral medicament capsule of the present invention is organized in treatment, three times on the one, 1～2 years old each 1～2,3～5 years old each 2～3,6～12 years old each 3～4, add equivalent brown sugar and take with milled congee ante cibum.The oral controlled trial capsule of contrast I group, usage is identical with the treatment group with consumption.The oral happiness grain slurry of contrast II group, three times on the one, 1～2 years old each 3ml of child, 3～5 years old each 5ml, 6～12 years old each 10ml.Weekly further consultation once, the record observation index, 2 months is a course of treatment, evaluates curative effect after treating a course of treatment, bans use of medicines such as other strengthening the spleen to promote digestion, immunomodulating, trace element during the treatment.
6. criterion of therapeutical effect: formulate clinical drug trial efficacy assessment standard of the present invention with reference to apositia efficacy assessment standard in the Chinese traditional Chinese medical science industry standard.
Produce effects: appetite is good after taking medicine 2 months, appetite and normal children of the same age, and 2 degree that turn for the better by and large or take a turn for the better, hyperhidrosis is normal or reduce 2 grades.
Effectively: anorexia alleviates 1 degree, and hyperhidrosis reduces 1 grade.
Invalid: symptom does not have significant change before and after the treatment.
7. therapeutic outcome: treatment group produce effects 39 examples, account for 75.00%, effective 9 examples account for 17.31%, and invalid 4 examples account for 7.69%, and total effective rate is 92.30%.Contrast I group produce effects 23 examples account for 54.76%, and effective 11 examples account for 26.19%, and invalid 8 examples account for 19.05%, and total effective rate is 80.95%.Contrast II group produce effects 8 examples account for 26.67%, and effective 15 examples account for 50.00%, and invalid 7 examples account for 23.33%, and total effective rate is 76.67%.Learn by statistics and handle, total effective rate treatment group is higher than contrast I group, contrast II group (p＜0.05, p＜0.01), and contrast I group is higher than contrast II group (p＜0.05).
The inventor has provided used raw material of Chinese medicine and the proportioning thereof of first embodiment of the invention (is example for 100 kilograms with production drug powder of the present invention):
Moschus 0.24kg Melanteritum 9.73kg Fructus Jujubae 24.33kg
Fructus Crataegi 24.33kg Rhizoma Dioscoreae 31.63kg Semen Arecae 9.74kg
In its proportioning, the weight portion of each component is:
20 parts in 8 portions of Fructus Jujubaes of 0.2 part of Melanteritum of Moschus
8 parts of 26 portions of Semen Arecaes of 20 portions of Rhizoma Dioscoreaes of Fructus Crataegi
The inventor has provided used raw material and the proportioning thereof of second embodiment of the invention (100kg is an example with production drug powder product of the present invention):
Moschus 0.39kg Melanteritum 13.11kg Fructus Jujubae 26.13kg
Fructus Crataegi 26.1 3kg Rhizoma Dioscoreae 22.28kg Semen Arecae 11.97kg
In its proportioning, the weight portion of each component is:
40 parts in 20 portions of Fructus Jujubaes of 0.6 part of Melanteritum of Moschus
18 parts of 34 portions of Semen Arecaes of 40 portions of Rhizoma Dioscoreaes of Fructus Crataegi
The inventor has provided used raw material and the proportioning thereof of third embodiment of the invention (100kg is an example with production drug powder product of the present invention):
Moschus 0.34kg Melanteritum 1 0.31kg Fructus Jujubae 27.49kg
25.77kg Rhizoma Dioscoreae 24.06kg Semen Arecae 12.03kg is cooked and stir on the mountain
In its proportioning, the weight portion of each component is:
32 parts in 12 portions of Fructus Jujubaes of 0.4 part of Melanteritum of Moschus
14 parts of 28 portions of Semen Arecaes of 30 portions of Rhizoma Dioscoreaes of Fructus Crataegi
More than provided the embodiment of the used raw material of Chinese medicine proportioning of preparation drug powder of the present invention, the proportioning of same applicable preparation identical weight medicine capsule of the present invention and the used raw material of Chinese medicine of medicinal tablet of the present invention.
More than three embodiment make medicinal tablet of the present invention (product 100kg of the present invention is an example with production, every heavy 0.3g) used raw material of Chinese medicine and the proportioning of adjuvant as follows:
The raw material of Chinese medicine that first embodiment is used and the proportioning of adjuvant are:
Moschus 0.23kg
Melanteritum 9.32kg
Fructus Jujubae 23.30kg
23.30kg is cooked and stir on the mountain
Rhizoma Dioscoreae 30.29kg
Semen Arecae 9.33kg
Magnesium stearate 0.23kg
10% starch gelatin slurry 4kg
The raw material of Chinese medicine that second embodiment is used and the proportioning of adjuvant are:
Moschus 0.38kg
Melanteritum 12.55kg
Fructus Jujubae 25.10kg
Fructus Crataegi 25.10kg
Rhizoma Dioscoreae 21.34kg
Semen Arecae 11.31kg
Magnesium stearate 0.23kg
10% starch gelatin slurry 4kg
The proportioning of the 3rd raw material of Chinese medicine that embodiment is used and adjuvant is:
Moschus 0.33kg
Melanteritum 9.88kg
Fructus Jujubae 26.33kg
Fructus Crataegi 24.68kg
Rhizoma Dioscoreae 23.04kg
Semen Arecae 11.52kg
Magnesium stearate 0.23kg
10% starch gelatin slurry 4kg
Function of the present invention: the spleen invigorating temperature, help digestion in transferring, benefiting QI and nourishing blood.
The present invention cures mainly: apositia.
Specification of the present invention: the heavy 0.5g of the every bag of powder, every gram contains crude drug 1g, every heavy 0.5g of capsule, every gram contains crude drug 1g, every heavy 0.3g of tablet, every gram contains crude drug 0.96g.
Usage and dosage of the present invention: every day three times; be grown up 5 in each powder 5 bags or 5 of capsules or tablet; 3～4 in 6～12 years old each powder 3～4 bags or 3～4 of capsules or tablet; 2～3 in 3～5 years old each powder 2～3 bags or 2～3 of capsules or tablet; 1～2 in 1～2 year old each powder 1～2 bag or 1～2 of capsule or tablet; add equivalent brown sugar, milled congee takes, and 2 months is a course of treatment.
Storage of the present invention: sealing lucifuge, shady and cool dry place storage.
Effect duration of the present invention: the effect duration of drug powder of the present invention, medicine capsule of the present invention, medicinal tablet of the present invention is 2 years.
Claims (4)
1. Chinese patent medicine for the treatment of apositia is characterized in that it is by the following weight proportion raw material medicament of formulation method preparation routinely:
20～40 parts in 8～20 portions of Fructus Jujubaes of 0.2～0.6 part of Melanteritum of Moschus
8～18 parts of 26～34 portions of Semen Arecaes of 20～40 portions of Rhizoma Dioscoreaes of Fructus Crataegi
2. according to the Chinese patent medicine of the described treatment apositia of claim 1, wherein the weight proportion of each raw material is:
25～35 parts in 10～15 portions of Fructus Jujubaes of 0.3～0.5 part of Melanteritum of Moschus
10～18 parts of 26～32 portions of Semen Arecaes of 25～35 portions of Rhizoma Dioscoreaes of Fructus Crataegi
3. according to the Chinese patent medicine of the described treatment apositia of claim 1, wherein the weight proportion of each raw material is:
32 parts in 12 portions of Fructus Jujubaes of 0.4 part of Melanteritum of Moschus
14 parts of 28 portions of Semen Arecaes of 30 portions of Rhizoma Dioscoreaes of Fructus Crataegi
4. according to the Chinese patent medicine of claim 1,2 or 3 described treatment apositia, it is characterized in that: said medicament is said powder or capsule or a tablet on the galenic pharmacy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98113029A CN1072949C (en) | 1998-11-27 | 1998-11-27 | Medicine for treating anorexia |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN98113029A CN1072949C (en) | 1998-11-27 | 1998-11-27 | Medicine for treating anorexia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1255338A CN1255338A (en) | 2000-06-07 |
| CN1072949C true CN1072949C (en) | 2001-10-17 |
Family
ID=5222814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN98113029A Expired - Fee Related CN1072949C (en) | 1998-11-27 | 1998-11-27 | Medicine for treating anorexia |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1072949C (en) |
-
1998
- 1998-11-27 CN CN98113029A patent/CN1072949C/en not_active Expired - Fee Related
Non-Patent Citations (3)
| Title |
|---|
| 《中国医药学报》1993年第8卷第2期 1993.2.28 午雪峤小儿阴虚临床论治经验 午雪峤 * |
| 《陕西中医》1992年第13卷第7期 1992.7.31 启脾汤治疗小儿厌食症250例和成斌 * |
| 《陕西中医》1992年第13卷第7期 1992.7.31 启脾汤治疗小儿厌食症250例和成斌;《中国医药学报》1993年第8卷第2期 1993.2.28 午雪峤小儿阴虚临床论治经验 午雪峤 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1255338A (en) | 2000-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1939477A (en) | Chinese-medicinal composition for treating enterogastric diseases | |
| CN100342889C (en) | Chinese medicine for treating gout | |
| CN102258735A (en) | Medicine for treating fore-stomach stony and impaction of rumen in cows and preparation method thereof | |
| CN1739734A (en) | Chinese medicine prepn for treating stomatitis and its prepn process | |
| CN101049323A (en) | Health protection medicine in use for treating chronic degenerative diseases, and producing method | |
| CN1201786C (en) | Traditional Chinese medicine composition for curing child's dyspepsia and cough and its preparing method | |
| CN1108804C (en) | Diabetes treating medicine and its prepn. method | |
| CN1726929A (en) | Compsn. of medication for treating diabetes | |
| CN1121867C (en) | Medicine for preventing and treating abortion | |
| CN1072949C (en) | Medicine for treating anorexia | |
| CN1973878A (en) | Medicine for treating children's stomachache and its prepn | |
| CN1634548A (en) | Medicine composition for treating viral hepatitis and its preparation method | |
| CN1879701A (en) | Cold-treating medicine and preparation method thereof | |
| CN1259095C (en) | Brain-quieting hypertension-treating medicine, and its preparing method and use | |
| CN1742879A (en) | Chinese medicine for reducing blood sugar and preparation thereof | |
| CN1248715C (en) | Stomachic medication and preparation method | |
| CN1140071A (en) | Anticancer drug and preparing method thereof | |
| CN100563706C (en) | A kind of pharmaceutical composition that is used for infantile diarrhea | |
| CN1872186A (en) | Compound capsule of Chinese date kernel, and preparation method | |
| CN1565556A (en) | Chinese drugs for treating preceded menstrual cycle and excessive menses due to blood heat | |
| CN1201742C (en) | Hypoglycemic health-care food for diabetes type II; | |
| CN1049148C (en) | Stomach-recovering capsule | |
| CN103181945A (en) | Novel application of luffa seeds | |
| CN1065755C (en) | Chinese compound medicine for treatment of hepatic calculus and cholecystitis | |
| CN1060659C (en) | Pill medicine for cancer and preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C06 | Publication | ||
| PB01 | Publication | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C19 | Lapse of patent right due to non-payment of the annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |